Herein, we reveal that mEVs exhibit a unique mechanism to facilitate systemic exposure through interaction with the FcRn in the intestines following oral administration, enabling effective gut-to-tumor oral drug delivery (Scheme 1). This evidence concerns the gene FCGRT and neoplasm.